NEW TREATMENT FOR SCORPION STINGS
FDA
approved the first specific treatment for Scorpion stings by Centruroids
scorpions in the US. Stings occur most frequently in infants and children. The
symptoms include shortness of breath, fluid in the lungs, breathing problems,
excess salivation, blurred vision, slurred speech, muscle twitching etc. If
left untreated, cases can be life threatening.
“Anascorp”, Centruroides Immune F (
ab’) 2 (Equine) injection, is made
from the plasma of horses immunized with scorpion venom. Anascorp was
designated as an Orphan drug by FDA. Anascorp may cause early or delayed
allergic reactions in people sensitive to horse proteins. The manufacturing
process for Anascorp includes steps to decrease the chance of allergic
reactions and to reduce the risk of transmission of viruses that may be present
in the plasma. The most common side effects are vomiting, fever, rash, nausea,
itchiness, headache, runny nose, and muscle pain.
Tina thomas
Sr lecturer
---------------------------------------------------------------------------------------------------
NEW TREATMENT FOR MOST
COMMON TYPE OF SKIN CANCER
Erivedge (Vismodegib)
was approved by the U.S. food and drug administration to treat adult patients
with basal cell carcinoma, the most common type of skin cancer. Basal cell
carcinoma is generally a slow growing and painless form of skin cancer that
starts in the top layer of the skin (epidermis).The cancer develops on areas of
skin that are regularly exposed to sunlight or other ultraviolet radiation.
Erivedge is
a pill taken once a day and works by inhibiting the hedgehog pathway, a pathway
that is active in most basal cell cancers and only a few normal tissues, such
as hair follicles. the most common side effects observed in patients treated
with Erivedge are muscle spasms, hair loss, weight loss, nausea, diarrhea, fatigue,
distorted sense of taste, decreased appetite, constipation, vomiting, and loss
of taste function in the tongue. Erivedge is marketed by Genentech, a member of
the Roche group.
Tina thomas
Sr Lecturer
No comments:
Post a Comment